Showing 4161-4170 of 8588 results for "".
- National Society for Cutaneous Medicine Endorses Use of GEP Testing for Melanomahttps://practicaldermatology.com/news/national-society-for-cutaneous-medicine-endorses-use-of-gep-testing-for-melanoma/2461597/The National Society for Cutaneous Medicine now recommends use of gene expression profile (GEP) testing in the clinical assessment and management of cutaneous melanoma (CM). The report provides usage guidelines and a framework for clinicians to integrate GEP testing into their CM
- Memantine May Improve Trichotillomania, Excoriation Disorderhttps://practicaldermatology.com/news/memantine-may-improve-trichotillomania-excoriation-disorder/2461594/The Alzheimer’s disease memantine effectively reduces symptoms of adults with trichotillomania and skin-picking disorder also known as excoriation disorder, new research shows. Researchers honed in on memantine based on earlier findings that revealed disorganized areas of white ma
- Study: Lycomato Carotenoid Supplement May Boost Skin Health and Appearancehttps://practicaldermatology.com/news/study-lycomato-carotenoid-supplement-boost-skin-health-and-appearance/2461592/Daily supplementation with Lycomato may improve fine lines, wrinkles, pore appearance brightness/radiance, skin tone evenness, dark spot intensity, smoothness, and firmness after four weeks of use, according to a new study&
- Fewer Cases of Melanoma, Cancers in Extracutaneous Sites Seen in Patients with Atopyhttps://practicaldermatology.com/news/fewer-cases-of-melanoma-cancers-in-extracutaneous-sites-seen-in-patients-with-atopy/2461591/Fewer cases of melanoma are observed in people with a history of atopic diseases, such as allergic asthma or rhinitis, than in nonatopic people, according to a new study in Melanoma Research. Specifically, the risk of melanoma in people with atopy was up to 50% lower than
- Landmark Data: Neoadjuvant Pembrolizumab Improves Outcomes for High-risk Melanoma Patientshttps://practicaldermatology.com/news/landmark-data-neoadjuvant-pembrolizumab-improves-outcomes-for-high-risk-melanoma-patients/2461589/Patients with high-risk melanoma who received pembrolizumab both before and after surgery had a significantly lower risk of their cancer recurring than patients who received the drug only after surgery. These results, published today in the
- Merz Aesthetics Taps Christina Aguilera as New Xeomin Brand Partnerhttps://practicaldermatology.com/news/merz-aesthetics-taps-christina-aguilera-as-new-xeomin-brand-partner/2461588/Christina Aguilera is the latest Xeomin (incobotulinumtoxinA) brand partner as Merz Aesthetics expands its ‘Beauty on Your Terms’ marketing campaign. Launched in August 2022, the campaign features multiple music icons in support of Xeomin.
- Candela Announces Health Canada Licences for Nordlys Multi-Application System and Frax Pro Devicehttps://practicaldermatology.com/news/candela-announces-health-canada-licences-for-nordlys-multi-application-system-and-frax-pro-device/2461586/Candela announced Health Canada licensing and the availability of the Nordlys multi-application platform, which features Selective Waveband Technology (SWT) and the dual-wavelength Frax Pro non-ablative fractional laser platform.[1-4] The Nordlys is designed to improve treatme
- Dyskerin May Signal When SCC Is On The Movehttps://practicaldermatology.com/news/dyskerin-may-signal-when-scc-is-on-the-move/2461585/The protein dyskerin may provide important clues as to how cutaneous squamous cell carcinoma tumors prepare themselves to migrate to the lymph nodes to metastasize other organs, a new study suggests. These cells stop consuming glucose so that they can survive by using LDL chol
- Bristol Myers Squibb Advances Melanoma Drug Candidate Opdivo in US and Europehttps://practicaldermatology.com/news/bristol-myers-squibb-advances-melanoma-drug-candidate-opdivo-in-us-and-europe/2461583/Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Application (BLA) for Opdivo (nivolumab) as monotherapy in the adjuvant setting for the treatment of patients with completely resected stage IIB or IIC melanoma. The company also announced t
- Study: Plugging Immune Cell Leakage from Tumors Could Improve MelanomaTreatmenthttps://practicaldermatology.com/news/study-plugging-immune-cell-leakage-from-tumors-could-improve-melanomatreatment/2461578/The number of specialized immune cells available for fighting skin cancer double when a new treatment blocks their escape from melanoma tumors, according to new research out of NYU Langone Health’s Perlmutter Cancer Center Combining a chemical blocker of immune cell exit with